3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
5
Lymphoma, T-Cell, Peripheral
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
Paclitaxel
30
Carboplatin
24
Cisplatin
11
Topotecan
8
liposomal doxorubicin
6
Hyperthermic Intraperitoneal Chemotherapy
6
mirvetuximab soravtansine
5
Cyclophosphamide
5
Drug Therapy
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
rucaparib
3
Peripheral Blood Stem Cell Transplantation
3
Neoadjuvant Therapy
3
Doxorubicin
3
Docetaxel
3
CP protocol
3
olaparib
2
liposomal amphotericin B
2
Surgical Procedures, Operative
2
Letrozole
2
Gemcitabine
2
trebananib
1
trastuzumab deruxtecan
1
phenoxodiol
1
pembrolizumab
1
oregovomab
1
niraparib
1
fluzoparib
1
epothilone B
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Ovarian Epithelial
×
1-dodecylpyridoxal
×
Clear all
NCT01281254
2017-12-02
TRINOVA-2
Amgen
Phase 3
Terminated
223 enrolled